Stifel’s Insight on hVIVO PLC
hVIVO PLC (AIM:HVO) Positive results from flu human challenge study
Positive results from influenza human challenge study conducted by hVIVO Pneumagen to advance antiviral candidate into further clinical studies
hVIVO PLC (AIM:HVO) Interim results
Strong first-half performance and record forward visibility Upgrade of Full Year Revenue and EBITDA Guidance
hVIVO PLC (AIM:HVO) Plans for a new larger state-of-the-art facility
Plans for a new larger state-of-the-art facility to meet growing demand
hVIVO PLC (AIM:HVO) Notice of Results
hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for
hVIVO PLC (AIM & Euronext: HVO) Trading update
Strong first-half performance and record order book On track to deliver full-year guidance and long-term sustainable growth
hVIVO PLC (AIM:HVO) Flu B challenge model
£13.1m contract with the global pharmaceutical client to develop an influenza B virus challenge model
hVIVO PLC (AIM:HVO) hMPV human challenge model
hVIVO to develop human metapneumovirus (hMPV) challenge model First client of the new hMPV model secured
Genflow Biosciences implements internal modifications to better align with its objectives in the US
Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order
hVIVO PLC Annual Report and Notice of AGM
hVIVO plc (AIM & Euronext: HVO), formerly known as Open Orphan plc, and a global leader in conducting human challenge clinical trials for infectious and respiratory disease products, has announced
hVIVO PLC FDA Breakthrough and Fast Track for US biotech
SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).